To conclusively evaluate TP53 requirement in melanoma cells that harbored wt-TP53, we adopted a twofold approach, (1) si-TP53-mediated rescue of AURKA inhibition-associated TP53 and p21Cip1 induction (Figures 3g and h), and (2) TP53 inhibitor Pifithrin-α-mediated suppression of TP53 transcriptional activity27 (Figure 3i). This evidence concerns the gene CDKN1A and melanoma.